作者
George Dangas, Usman Baber, Samin Sharma, Gennaro Giustino, Shamir Mehta, David J Cohen, Dominick J Angiolillo, Samantha Sartori, Rishi Chandiramani, Carlo Briguori, Dariusz Dudek, Javier Escaned, Kurt Huber, Timothy Collier, Ran Kornowski, Vijay Kunadian, Upendra Kaul, Keith Oldroyd, Gennaro Sardella, Richard Shlofmitz, Bernhard Witzenbichler, Han Ya-Ling, Stuart Pocock, C Michael Gibson, Roxana Mehran
发表日期
2020/5/19
期刊
Journal of the American College of Cardiology
卷号
75
期号
19
页码范围
2414-2424
出版商
American College of Cardiology Foundation
简介
Background
Whether a regimen of ticagrelor monotherapy attenuates bleeding complications without increasing ischemic risk in patients undergoing complex percutaneous coronary intervention (PCI) is unknown.
Objectives
The purpose of this study was to evaluate the effect of ticagrelor monotherapy versus ticagrelor plus aspirin in patients undergoing complex PCI from the randomized, double-blind, placebo-controlled TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial.
Methods
In the TWILIGHT trial, after 3 months of ticagrelor plus aspirin, event-free and adherent patients remained on ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. Complex PCI was defined as any of the following: 3 vessels treated, ≥3 lesions treated, total stent length >60 mm, bifurcation with 2 stents implanted, atherectomy device use, left main PCI, surgical …
学术搜索中的文章
G Dangas, U Baber, S Sharma, G Giustino, S Mehta… - Journal of the American College of Cardiology, 2020